Psychedelics assisting therapy, or therapy assisting psychedelics? The importance of psychotherapy in psychedelic-assisted therapy
Open accessAbstract
There is notable controversy about the role of psychotherapy in clinical trials of psychedelic-assisted therapy (PAT). This heated and perpetually evolving debate informs questions such as how much therapy should accompany a psychedelic intervention (Marseille et al., 2022), what type of therapy most effectively complements psychedelic administration (Cavarra et al., 2022;Yaden et al., 2022), and even whether psychotherapy should always be included (Goodwin et al., 2023;Earleywine et al., 2024;Schenberg, 2024). Recent events, namely the rejection by the Food and Drug Administration (FDA) of Lykos Therapeutics' application to approve MDMA-assisted therapy (MDMA-AT) as a treatment for PTSD, has brought forth some of the intricacies within this debate. That governing body's role is to approve pharmacological agents, not psychotherapies. The FDA was likely unfamiliar with the complication of including therapy with MDMA-AT, rather than evaluating the administration of MDMA as a standalone pharmacological intervention. This highlights the novelty of PAT in medicalized settings, and underscores the controversy of including bona fide psychotherapy as a necessary component of psychedelic drug administration.From our perspective, PAT is a unique psychiatric intervention in that it is genuinely a combined treatment, involving the administration of a psychedelic substance such as psilocybin or MDMA within the context of psychotherapy. Thus, PAT synergizes elements of pharmacological enhancement along with psychological and relational learning and healing. The application of psychedelics seems to potentiate cognitive, emotional, and behavioral change and help psychotherapy to be more effective (Cavarra et al., 2022;Grunder et al., 2024;Nayak & Johnson, 2021). Additionally, like most psychotherapies, PAT is a relational intervention. There is emerging evidence, consistent with the body of evidence in the psychotherapy literature, suggesting that the quality of the relationship between PAT therapists and patients is critically important for the success of the treatment (Levin et al., 2024;Murphy et al., 2022;Zeifman et al., 2024). The emotional impact of the real relationship developed between therapists and patients is crucial to the patient's healing, not a perfunctory safety protocol nor a peripheral afterthought.We champion the essential role of psychotherapy within the arc of PAT in helping patients attain meaningful relief from their psychological distress, and we encourage a rigorous scientific examination of which types and doses of therapy may optimize the delivery of PAT.Commented [JZ1]: This word was erroneously included in the title of the article, as it was "auto-read" as being part of the title. I am deleting it here and it should not be included in the title of the paper.While some researchers support the necessary inclusion of psychotherapy within PAT (Cavarra et al., 2022;Deckel et al., 2024;Earleywine et al., 2024;Schenberg et al., 2024), others have made a case for not including psychotherapy as a component of psychedelic administration. Goodwin et al. (2023) advance this argument, stating that there is minimal evidence to confirm the belief that PAT is a truly combined treatment and a form of enhanced or catalyzed psychotherapy. They suggest that psychedelic administration, with some psychological support for safety, is often all that is necessary to produce meaningful change for many patients suffering from serious mental health conditions, and this configuration should be the general context in which we study the effects of psychedelic administration on psychosocial health.They first claim the type of psychotherapy used in some PAT trials has been nondirective counseling, and that nondirective counseling is not an evidence-based treatment for conditions targeted by PAT, including treatment-resistant depression, PTSD, and substance use disorders. Our perspective is that PAT is not an la carte platter, in which the "best" treatment is constructed by extracting elements of other effective non-psychedelic treatments (like evidence-based psychotherapies) and forcing them into the framework of PAT. Rather than cobbling together specific ingredients to produce an evidence-based treatment package, we advocate for the examination of which therapies are most efficacious when delivered in concert with psychedelic administration and applied in a PAT setting. If there is preliminary evidence that administration of psychedelics with psychological support could help treat a psychiatric condition, how might it further improve the outcome of psychedelic administration to pair it with thoughtfully-selected psychotherapy approaches, principles, or techniques that are understood to be efficacious? We will not know unless we study this phenomenon. As stated by Earleywine et al. (2024), "only data can answer this question. A clinical trial could compare groups with and without extensive preparation and integration." The s
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Psychedelics enhance psychotherapeutic outcomes by facilitating cognitive, emotional, and behavioral transformations.
“Psychedelics have been shown to enhance psychotherapeutic outcomes by facilitating cognitive, emotional, and behavioral transformations (103, 106, 127).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [103]
The Introduction says psychedelic use “seems to potentiate cognitive, emotional, and behavioral change” and help psychotherapy become more effective. That supports the proposed mechanism and outcome, but the citing sentence’s “have been shown” states the conclusion more firmly than this passage does. (LLM, conf=0.84)
Experimental — accuracy not yet measuredThe flexibility of psychoanalytic therapy makes it particularly compatible with psychedelics, whose effects are often unpredictable and require therapists to adapt to patients' evolving processes.
“This flexibility makes it particularly compatible with psychedelics, whose effects are often unpredictable and require therapists to adapt to patients’ evolving processes (103).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [103]
In “What type of therapy should accompany PAT?” (page unavailable), the paper says psychedelic sessions are often difficult to predict and therapists must remain open to patients’ processes. It describes flexibility as important in psychotherapy generally, but does not specifically identify psychoanalytic therapy as particularly compatible with psychedelics. (LLM, conf=0.86)
Experimental — accuracy not yet measuredThe role of psychotherapy in psychedelic treatment remains a subject of debate.
“The role of psychotherapy in psychedelic treatment remains a subject of debate (103).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [103]
PAT is inherently relational, in keeping with psychoanalytic therapy's emphasis on therapist-patient dynamic.
“Zamaria et al. (103) describe PAT as inherently relational, which is in keeping with the contemporary ethos of psychoanalytic therapy, where the importance of the therapist-patient dynamic helps facilitate change.”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bergin and Garfield's Handbook of Psychotherapy and Behavior Change
Lambert, M. J. (2003) · Cited by 3,383 · see citing works
Meta-analysis of psychotherapy outcome studies.
Smith, M. L., & Glass, G. V. (1977) · American Psychologist · doi:10.1037/0003-066x.32.9.752 · Cited by 2,154 · see citing works
The Great Psychotherapy Debate: The Evidence for What Makes Psychotherapy Work
Wampold, B. E. (2015) · doi:10.4324/9780203582015 · Cited by 1,773 · see citing works
"Are all psychotherapies equivalent?"
Stiles, W. B., Shapiro, D. A., & Elliott, R. (1986) · American Psychologist · doi:10.1037//0003-066x.41.2.165 · Cited by 487 · see citing works
Expanding the lens of evidence-based practice in psychotherapy: A common factors perspective.
Laska, K. M., Gurman, A. S., & Wampold, B. E. (2014) · Psychotherapy · doi:10.1037/a0034332 · Cited by 443 · see citing works
"Are all psychotherapies equivalent?"
Stiles, W. B., Shapiro, D. A., & Elliott, R. (1986) · American Psychologist · doi:10.1037/0003-066x.41.2.165 · Cited by 322 · see citing works
The use of the psychological flexibility model to support psychedelic assisted therapy
Watts, R., & Luoma, J. B. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.12.004 · Cited by 269 · see citing works
Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression
Murphy, R., Kettner, H., Zeifman, R., Giribaldi, B., Kartner, L., Martell, J., Read, T., Murphy-Beiner, A., Baker-Jones, M., Nutt, D., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.788155 · Cited by 250 · see citing works
Evidence-Based Therapy Relationships
Norcross, J. C., & Lambert, M. J. (2011) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199737208.003.0001 · Cited by 234 · see citing works
Must Psilocybin Always “Assist Psychotherapy”?
Goodwin, G. M., Malievskaia, E., Fonzo, G. A., & Nemeroff, C. B. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20221043 · Cited by 191 · see citing works
Sloshower, J., Guss, J., Krause, R., Wallace, R. M., Williams, M. T., Reed, S., & Skinta, M. D. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.002 · Cited by 171 · see citing works
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P. C., & Mento, C. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.887255 · Cited by 171 · see citing works
Budd, R., & Hughes, I. (2009) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.648 · Cited by 149 · see citing works
Treatment with psychedelics is psychotherapy: beyond reductionism
Gründer, G., Brand, M., Mertens, L. J., Jungaberle, H., Kärtner, L., Scharf, D., Spangemacher, M., & Wolff, M. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00363-2 · Cited by 119 · see citing works
Psychedelics and psychotherapy: Cognitive-behavioral approaches as default
Yaden, D. B., Earp, D., Graziosi, M., Friedman-Wheeler, D., Luoma, J. B., & Johnson, M. W. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.873279 · Cited by 110 · see citing works
Brennan, W., & Belser, A. B. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.866018 · Cited by 90 · see citing works
Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300501 · Cited by 82 · see citing works
Research abuses against people of colour and other vulnerable groups in early psychedelic research
Strauss, D., de la Salle, S., Sloshower, J., & Williams, M. T. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2021-107262 · Cited by 75 · see citing works
Psychedelics and psychotherapy
Nayak, S., & Johnson, M. W. (2021) · Pharmacopsychiatry · doi:10.1055/a-1312-7297 · Cited by 71 · see citing works
The economics of psychedelic-assisted therapies: A research agenda
Marseille, E. A., Bertozzi, S., & Kahn, J. G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1025726 · Cited by 56 · see citing works
Zeifman, R. J., Kettner, H., Ross, S., Weiss, B., Mithoefer, M. C., Mithoefer, A. T., & Wagner, A. C. (2024) · European Journal of Psychotraumatology · doi:10.1080/20008066.2023.2297536 · Cited by 37 · see citing works
Is Poorly Assisted Psilocybin Treatment an Increasing Risk?
Schenberg, E. E., King, F., da Fonseca, J. E., & Roseman, L. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230664 · Cited by 31 · see citing works
Psilocybin Without Psychotherapy: A Cart Without a Horse?
Earleywine, M., Leo, J. A. D., Bhayana, D., Rajanna, B., & Scott, K. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230572 · Cited by 24 · see citing works
Psychedelic-assisted therapy” must not be retired
Deckel, G. M., Lepow, L. A., & Guss, J. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230667 · Cited by 21 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Lambert, 2013, “The efficacy and effectiveness of psychotherapy,”, 169
Cited by
Sorted by citations
Albert, A. E., & Back, A. L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1529427 · Cited by 6 · see citing works
Jones, J. L. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1565852 · Cited by 6 · see citing works
Dwyer, J. L., Johnston, R. B., O’Callaghan, C. C., & Ross, M. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.12.002 · Cited by 5 · see citing works
Yehuda, R., Lehrner, A. L., Sperka, M., Zaretsky, T. G., Pratchett, L. C., Haznedar, M. M., & Lepow, L. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100008 · Cited by 4 · see citing works
Self-citationPsychedelics and mental health: reimagining care through science, insight, and compassion
Mikellides, G., & Kyriazis, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1649929 · Cited by 4 · see citing works
Ledwos, N., Baer, J., Husain, M. I., Blumberger, D. M., Patterson, R., Hollingdrake, E., Cheung, E. S. L., Hawco, C. S., Zrenner, C., Zrenner, B., et al. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10895 · Cited by 3 · see citing works
Sevelius, J. M., Golden, R. L., Stott, B. L., Kozicz, N. O., Mukerjee, R., Cluesman, S. R., Jones, T., & Cornelius, T. M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1727487 · Cited by 2 · see citing works
State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder
Morland, L. A., Rothbaum, B. O., Sippel, L. M., Maples‐Keller, J. L., & Schnurr, P. P. (2026) · Journal of Traumatic Stress · doi:10.1002/jts.70060 · Cited by 2 · see citing works
Not a Standalone Treatment: Considerations for Psychedelic‐Assisted Therapy
Murphy, S., Stewart, E., Winship, J. R., Kampel, L., Stiel, B., & Ellis, J. (2026) · Brain and Behavior · doi:10.1002/brb3.71280 · Cited by 2 · see citing works
Morland, L. A., Knopp, K. C., Khalifian, C. E., & Stauffer, C. S. (2025) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2025.04.001 · Cited by 2 · see citing works
Dleštíková, T. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.105067 · Cited by 1 · see citing works
Dölen, G., & Wilkinson, M. L. (2026) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-112723-045129 · Cited by 1 · see citing works
Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians
Beichmann, K., Catzeflis, P., Aicher, H., Seragnoli, F., Calder, A. E., Amrani, A., & Hasler, G. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261448745 · Cited by 1 · see citing works
Mele, M. L., & Federici, S. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1880744 · Cited by 1 · see citing works
Johnson, D. E., Meshkat, S., Kaczmarek, E. S., Rabin, J. S., Brudner, R. M., Chisamore, N., Doyle, Z., Bawks, J., Riva-Cambrin, J., Mansur, R. B., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111565 · Cited by 1 · see citing works
Mitchell, J., Neitzke‐Spruill, L., Mathai, D. S., Robinson, J. O., Kazan, Z., Averill, L. A., & McGuire, A. L. (2026) · Translational Behavioral Medicine · doi:10.1093/tbm/ibag027 · Cited by 1 · see citing works
Lehrner, A. L., Sperka, M., Lepow, L., Pratchett, L. C., Zaretsky, T. G., Haznedar, M. M., & Yehuda, R. (2026) · Psychedelic Medicine · doi:10.1177/28314425261429233 · Cited by 1 · see citing works
Self-citationQuestions and Concerns About MDMA-Assisted Therapy (MDMA-AT) in Veterans with PTSD Symptoms
Earleywine, M., Holley, C. K., MacConnel, H. A., & Farmer, S. L. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2570938
Kamene, K. (2026) · Premier Journal of Neuroscience · doi:10.70389/pjn.100014
Liberati, E., Curran, H. V., Fonagy, P., Clements, H., Lemma, A., McAlpine, R. G., Nutt, D. J., Schlag, A. K., & Kamboj, S. K. (2026) · PLoS ONE · doi:10.1371/journal.pone.0350728
Fletcher, K., Ezard, N., Siefried, K. J., van der Helder, S., Freestone, J., Brett, J., May, R., Acheson, L. S., & Clifford, B. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1873497
The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review
Ferreira, F. G. D. P., Fernandes, J. A. B., Filev, R., da Silveira, D. X., & Fidalgo, T. M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261453850
The Evolution of Psychedelics and Psychedelic-Assisted Therapy
Brar, G., Lally, K., Kelly, J. R., & O'Connell, H. P. (2026) · Springer eBooks · doi:10.1007/978-3-032-27009-2_16
What About Psycholytic Therapy? A Historical Revisiting of Psychedelics Assisting Psychotherapy
Zaher, I., & Richard, J. (2026) · Psychedelic Medicine · doi:10.1177/28314425261455416
Psychedelic Knowledge and Attitudes Among Saudi Medical and Psychology Students
Alharbi, A. R., Alqahtani, S. M., & Alzahrani, O. A. (2026) · Journal of Bioscience Studies · doi:10.65761/jbs.2026.72
Psychedelics in the Future of Global Mental Healthcare
Aleksandrova, L. R., Thiessen, K. A., Chen, F. X. F., Phillips, A. G., Schütz, C. G., & Krausz, M. (2026) · Springer eBooks · doi:10.1007/978-3-319-70134-9_174-1
From regulation to practice: A scoping review of prescribers’ roles in psilocybin-assisted therapy
Bélanger, G., Chang, S.-L., Masse-Grenier, M., Tremblay, M.-J., Farzin, H., Garel, N., & Dorval, M. (2026) · Drug Science Policy and Law · doi:10.1177/20503245261494890
Clinical Evidence on Psilocybin and Its Representation in Media Reporting
Madden, K., Flood, B., Kashir, I., Ahmad, R., Ali, H., Petranker, R., MacKillop, J., & Adili, A. F. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.38843
- Authors
- Zamaria, J. A., Fernandes-Osterhold, G., Shedler, J., & Yehuda, R.
- Affiliations
- University of California, San Francisco (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Zamaria, Joseph A.
- Venue
- Frontiers in Psychology
- Publisher
- Frontiers Media SA
- Published
- 2025-02-05
- Volume
- 16
- Pages
- 1505894-1505894
- ISSN
- 1664-1078 (ISSN-L)
- PMC
- PMC11835864
- OpenAlex
- W4407181198
- Semantic Scholar
- 7ef361af345c4d2f4daff8f02ced34004ff09bf0
- Cited by
- 29
- References
- 23
- Citations by year
- 2026: 20 · 2025: 9
- FWCI
- 26.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psychedelic therapy, psychotherapy, MDMA-assisted psychotherapy, psilocybin-assisted therapy, therapeutic relationship, combined psychotherapy and pharmacotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review